U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H8ClNS.ClH
Molecular Weight 198.113
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOMETHIAZOLE HYDROCHLORIDE

SMILES

Cl.CC1=C(CCCl)SC=N1

InChI

InChIKey=OFXYKSLKNMTBHK-UHFFFAOYSA-N
InChI=1S/C6H8ClNS.ClH/c1-5-6(2-3-7)9-4-8-5;/h4H,2-3H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H8ClNS
Molecular Weight 161.652
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chlormethiazole has sedative, hypnotic, anticonvulsant and neuroprotective properties. This drug is approved in different counties under the different brand name (e.g., Heminevrin) and is used for the management of restlessness and agitation in the elderly, short-term treatment of severe insomnia in the elderly and treatment of alcohol withdrawal symptoms. Clomethiazole interacts with the picrotoxin/barbiturate site of the GABAA-receptor-chloride channel complex. Clomethiazole is pharmacologically distinct from both the benzodiazepines and the barbiturates. Given alone its effects on respiration are slight and the therapeutic index high.

Originator

Curator's Comment: # Hoffmann-La Roche

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: picrotoxin/barbiturate site of the GABAA-receptor-chloride channel complex
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Heminevrin

Approved Use

Clomethiazole is a short acting hypnotic and sedative with anticonvulsant effect. It is used for the: management of restlessness and agitation in the elderly, short term treatment of severe insomnia in the elderly and treatment of alcohol withdrawal symptoms where close hospital supervision is also provided.
Primary
Heminevrin

Approved Use

Clomethiazole is a short acting hypnotic and sedative with anticonvulsant effect. It is used for the: management of restlessness and agitation in the elderly, short term treatment of severe insomnia in the elderly and treatment of alcohol withdrawal symptoms where close hospital supervision is also provided.
Primary
Heminevrin

Approved Use

Clomethiazole is a short acting hypnotic and sedative with anticonvulsant effect. It is used for the: management of restlessness and agitation in the elderly, short term treatment of severe insomnia in the elderly and treatment of alcohol withdrawal symptoms where close hospital supervision is also provided.
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Management of restlessness and agitation in the elderly: one capsule three times daily. Severe insomnia in the elderly: 1 - 2 capsules before going to bed. The lower dose should be tried first. As with all psychotropic drugs, treatment should be kept to a minimum, reviewed regularly and discontinued as soon as possible. Alcohol withdrawal states: Clomethiazole is not a specific 'cure' for alcoholism. Alcohol withdrawal should be treated in hospital or, in exceptional circumstances, on an outpatient basis by specialist units when the daily dosage of clomethiazole must be monitored closely by community health staff. The dosage should be adjusted to patient response. The patient should be sedated but rousable. A suggested regimen is: Initial dose: Day 1, first 24 hours: Day 2: Day 3: Days 4 to 6: 2 to 4 capsules, if necessary repeated after some hours. 9 to 12 capsules, divided into 3 or 4 doses. 6 to 8 capsules, divided into 3 or 4 doses. 4 to 6 capsules, divided into 3or 4 doses. A gradual reduction in dosage until the final dose.
Route of Administration: Oral
Using in vitro grease-gap recordings, it was shown that chlormethiazole inhibited epileptiform activity in neocortical slices superfused with Mg(2+)-free medium (IC(50) approximately 200 microM). At an antiepileptic concentration (300 microM), chlormethiazole potentiated the action of exogenously applied GABA (1 mM) but did not affect responses to the glutamate receptor agonists N-methyl-D-aspartate (10 microM) or L-quisqualic acid (3 microM). The GABA(A) receptor antagonist N-methyl-bicuculline (50 microM) reduced chlormethiazole's potency to inhibit the epileptiform activity. These results indicated that chlormethiazole's anticonvulsant action was likely mediated by potentiating GABA(A)ergic inhibition rather than by antagonising glutamatergic excitation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:53:14 GMT 2023
Edited
by admin
on Sat Dec 16 08:53:14 GMT 2023
Record UNII
85223EMG44
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOMETHIAZOLE HYDROCHLORIDE
MI  
Common Name English
CHLORMETHIAZOLE HYDROCHLORIDE
Common Name English
THIAZOLE, 5-(2-CHLOROETHYL)-4-METHYL-, HYDROCHLORIDE (1:1)
Systematic Name English
5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE HYDROCHLORIDE
Systematic Name English
CLOMETHIAZOLE HYDROCHLORIDE [MI]
Common Name English
Code System Code Type Description
PUBCHEM
19035073
Created by admin on Sat Dec 16 08:53:14 GMT 2023 , Edited by admin on Sat Dec 16 08:53:14 GMT 2023
PRIMARY
EPA CompTox
DTXSID80597589
Created by admin on Sat Dec 16 08:53:14 GMT 2023 , Edited by admin on Sat Dec 16 08:53:14 GMT 2023
PRIMARY
CAS
6001-74-7
Created by admin on Sat Dec 16 08:53:14 GMT 2023 , Edited by admin on Sat Dec 16 08:53:14 GMT 2023
PRIMARY
MERCK INDEX
m3645
Created by admin on Sat Dec 16 08:53:14 GMT 2023 , Edited by admin on Sat Dec 16 08:53:14 GMT 2023
PRIMARY Merck Index
FDA UNII
85223EMG44
Created by admin on Sat Dec 16 08:53:14 GMT 2023 , Edited by admin on Sat Dec 16 08:53:14 GMT 2023
PRIMARY
DRUG BANK
DBSALT002018
Created by admin on Sat Dec 16 08:53:14 GMT 2023 , Edited by admin on Sat Dec 16 08:53:14 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY